HLB group stocks showed strength across the board on the afternoon of the 6th. HLB Pharmaceutical and HLB Biostep soared to their daily price limits, while other major affiliates such as HLB Life Science and HLB Global also posted double-digit gains. As of 1:37 p.m. that day, all eight HLB group stocks were on the rise, according to quoted prices.

■ HLB Pharmaceutical and HLB Biostep Hit Price Ceiling... All 8 Group Stocks Rise

As of 1:37 p.m. on the 6th, HLB was trading at 46,600 won, up 15.20% from the previous trading day. Expanding its intraday gains, it is leading the broad strength of the group's stocks.

HLB Pharmaceutical hit the daily price limit, rising 29.97% to 13,010 won. HLB Biostep also climbed to its price limit, surging 29.91% to 3,735 won.

Buying interest is also flowing into other group stocks. HLB Life Science was trading up 21.95% at 4,360 won, and HLB Global rose 18.85% to 2,105 won. HLB Therapeutics gained 14.77% to 2,835 won, and HLB Panagine climbed 14.47% to 1,408 won. HLB Innovation also showed strength, rising 9.45% to 17,830 won.

■ FDA cGMP Inspection of Liver Cancer Drug Rivoceranib Classified as 'VAI'

The market is also paying attention to news related to HLB's liver cancer drug reported that day. HLB announced that the U.S. Food and Drug Administration (FDA) classified the results of its regular Current Good Manufacturing Practice (cGMP) inspection of Chinese contract manufacturer Hansoh Pharmaceutical's facility, which produces the finished liver cancer drug 'rivoceranib,' as 'Voluntary Action Indicated (VAI).'

According to HLB, VAI is a classification given when some issues are found during an inspection but are judged to be at a level the company can voluntarily correct, meaning no separate regulatory action is required.

Elevar Therapeutics, an HLB subsidiary, is preparing the data needed to resubmit the new drug application together with Hansoh Pharmaceutical.

However, as stock prices can change quickly during trading hours, whether the current gains will hold until the close remains to be seen. In particular, for stocks with heightened short-term volatility, related disclosures and future regulatory approval procedures should also be checked.

[This article was written based on provided market price data and company announcements and is for informational purposes only. It does not recommend the purchase or sale of any specific stock. Intraday prices may change afterward, and investment decisions and their consequences are the responsibility of the investor.]